Condition: Prostate Cancer · PET/CT · Sponsor: Anhui Provincial Hospital
To prospectively evaluate the radiodrug biodistribution of a novel PET imaging agent \[18F\]AlF-PSMA-N5 in different organs of prostate cancer patients and its diagnostic efficacy in the diagnosis, recurrence and metastasis of prostate cancer, and to compare with \[18F\]F-DCFPyL.
This description comes directly from the study's public registry record.
Qiang Xie, MD · 13721108043 · xieqiang1980@ustc.edu.cn
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of China University of Science and Technology（Anhui Provincial Hospital） | Hefei, Anhui, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06756334